Cara Therapeutics Inc (NASDAQ:CARA) has been assigned an average rating of “Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $24.03.
Several research firms have recently commented on CARA. Zacks Investment Research upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 21st. BidaskClub lowered shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 1st. Canaccord Genuity set a $25.00 price target on shares of Cara Therapeutics and gave the company a “buy” rating in a report on Thursday, December 20th. Piper Jaffray Companies set a $27.00 price target on shares of Cara Therapeutics and gave the company a “buy” rating in a report on Thursday, December 20th. Finally, Janney Montgomery Scott began coverage on shares of Cara Therapeutics in a report on Thursday, December 20th. They issued a “buy” rating and a $13.36 price target for the company.
In related news, CFO Mani Mohindru sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $12.55, for a total transaction of $56,475.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Frederique Ph.D. Menzaghi sold 4,300 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The stock was sold at an average price of $12.53, for a total transaction of $53,879.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 128,942 shares of company stock valued at $1,871,450. 6.70% of the stock is currently owned by company insiders.
Shares of NASDAQ:CARA traded down $0.15 during trading hours on Friday, hitting $18.80. The company’s stock had a trading volume of 277,288 shares, compared to its average volume of 655,396. Cara Therapeutics has a 52 week low of $11.46 and a 52 week high of $24.30. The firm has a market cap of $684.83 million, a P/E ratio of -9.13 and a beta of 2.68.
Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.07. The business had revenue of $5.53 million during the quarter, compared to the consensus estimate of $3.35 million. Sell-side analysts expect that Cara Therapeutics will post -2.31 EPS for the current fiscal year.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Further Reading: How Does the Quiet Period Work?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.